OPKO Health (NASDAQ:OPK) Issues Quarterly Earnings Results, Beats Expectations By $0.09 EPS

OPKO Health (NASDAQ:OPK) released its earnings results on Thursday. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09, Zacks reports. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%.

OPKO Health Price Performance

Shares of OPK traded down $0.03 during mid-day trading on Thursday, reaching $1.63. The company had a trading volume of 4,866,477 shares, compared to its average volume of 2,824,394. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The company has a market capitalization of $1.11 billion, a P/E ratio of -8.58 and a beta of 1.63. OPKO Health has a twelve month low of $0.86 and a twelve month high of $1.76. The company’s 50-day moving average is $1.54 and its 200-day moving average is $1.55.

Insider Activity at OPKO Health

In other news, CEO Phillip Md Et Al Frost acquired 500,000 shares of the firm’s stock in a transaction on Wednesday, December 11th. The shares were purchased at an average cost of $1.56 per share, with a total value of $780,000.00. Following the completion of the purchase, the chief executive officer now owns 212,411,477 shares of the company’s stock, valued at $331,361,904.12. This represents a 0.24 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have purchased a total of 1,521,609 shares of company stock valued at $2,313,710 in the last 90 days. 47.26% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research report on Wednesday, January 8th. Barrington Research reissued an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a report on Friday, November 8th. Finally, StockNews.com lowered OPKO Health from a “hold” rating to a “sell” rating in a research note on Wednesday, January 15th.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.